The therapeutic potential of targeting minimal residual disease in melanoma

The therapeutic potential of targeting minimal residual disease in melanoma

Abstract Background Cutaneous melanoma is a lethal form of skin cancer with morbidity and mortality rates highest amongst European, North American and Australasian populations. The developments of targeted therapies (TTs) directed at the oncogene BRAF and its downstream mediator MEK, and immune chec...

Full description

Bibliographic Details
Main Authors: Riyaben P Patel, Pretashini M Somasundram, Lorey K. Smith, Karen E. Sheppard, Grant A. McArthur
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Clinical and Translational Medicine
Subjects:
acquired resistance
BRAF/MEK inhibitors
combination treatment
cross‐resistance
immune checkpoint inhibitors
intrinsic resistance
Online Access:https://doi.org/10.1002/ctm2.1197

Internet

https://doi.org/10.1002/ctm2.1197

Similar Items